Discovery of potent inhibitors of α-synuclein aggregation using structure-based iterative learning.

ABSTRACT: Machine learning methods hold the promise to reduce the costs and the failure rates of conventional drug discovery pipelines. This issue is especially pressing for neurodegenerative diseases, where the development of disease-modifying drugs has been particularly challenging. To address this problem, we describe here a machine learning approach to identify small molecule inhibitors of α-synuclein aggregation, a process implicated in Parkinson's disease and other synucleinopathies. Because the proliferation of α-synuclein aggregates takes place through autocatalytic secondary nucleation, we aim to identify compounds that bind the catalytic sites on the surface of the aggregates. To achieve this goal, we use structure-based machine learning in an iterative manner to first identify and then pr

SUBMITTER: Horne RI 

PROVIDER: S-EPMC11062903 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature